Home > Insider Trading > Filing (0000899243-19-013262)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1563880	Trevi Therapeutics Inc.	TRVI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1385155	P David Meeker	C/O Trevi Therapeutics, Inc. 195 Church Street, 14Th Floor New Haven CT 06510		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-05-09	300,536	$0.00	300,536	No	4	C	Direct
Common Stock	Acquisiton	2019-05-09	27,432	$0.00	327,968	No	4	C	Indirect	By Trevi 2014 Irrevocable Trust
Common Stock	Acquisiton	2019-05-09	13,271	$0.00	341,239	No	4	C	Indirect	By Spinnaker Trust as Trustee for Trevi 2014 Irrevocable Trust
Common Stock	Acquisiton	2019-05-09	11,250	$10.00	352,489	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Indirect	By Trevi 2014 Irrevocable Trust
No	4	C	Indirect	By Spinnaker Trust as Trustee for Trevi 2014 Irrevocable Trust
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-05-09	924,880	$0.00	128,243	$0.00
Common Stock	Series A Preferred Stock	Disposition	2019-05-09	192,000	$0.00	27,432	$0.00
Common Stock	Series A Preferred Stock	Disposition	2019-05-09	95,712	$0.00	13,271	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-05-09	869,565	$0.00	116,375	$0.00
Common Stock	Series C Preferred Stock	Disposition	2019-05-09	478,951	$0.00	55,918	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Direct
No	4	C	Direct

Footnotes

On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
On May 9, 2019, the Series B Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.